Cargando…

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy

Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can treat hospitalized patients with COVID-19 disease. In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreras, C., Pascual-Miguel, B., Mestre-Durán, C., Navarro-Zapata, A., Clares-Villa, L., Martín-Cortázar, C., De Paz, R., Marcos, A., Vicario, J. L., Balas, A., García-Sánchez, F., Eguizabal, C., Solano, C., Mora-Rillo, M., Soria, B., Pérez-Martínez, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947351/ https://www.ncbi.nlm.nih.gov/pubmed/33718360 http://dx.doi.org/10.3389/fcell.2021.620730

Ejemplares similares

A phase I/II dose-escalation single center study to evaluate the safety of infusion of memory t cells as adoptive therapy in coronavirus pneumonia and /or lymphopenia (release)
por: Perez-Martinez, A., et al.
Publicado: (2021)

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
por: Pérez-Martínez, A., et al.
Publicado: (2021)

Donor selection for adoptive cell therapy with CD45RA(−) memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release
por: Al-Akioui-Sanz, Karima, et al.
Publicado: (2023)

Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210)
por: Ferreras, C., et al.
Publicado: (2023)

Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
por: Herrera, Lara, et al.
Publicado: (2021)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez, Antonio, et al.
Publicado: (2022)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez-Martinez, Antonio, et al.
Publicado: (2023)

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
por: Pérez-Martínez, Antonio, et al.
Publicado: (2021)

Immunotherapy: TIMING OF DONOR SELECTION ON CD45RA-MEMORY T CELLS AS ADOPTIVE CELL THERAPY FOR COVID-19
por: Al-Akioui, K., et al.
Publicado: (2022)

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
por: García-García, I., et al.
Publicado: (2021)

Cellular and Humoral Responses from Sars-Cov-2 Specific CD45RA- Memory T Cells from Convalescent and Naive Donors. Clinical Application As an Adoptive Cell Therapy for COVID-19
por: Sanz, Karima AL-Akioui, et al.
Publicado: (2022)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells
por: Mestre-Durán, Carmen, et al.
Publicado: (2023)

Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours
por: Ferreras, Cristina, et al.
Publicado: (2021)

Familial CD45RA(–) T cells to treat severe refractory infections in immunocompromised patients
por: Al-Akioui Sanz, Karima, et al.
Publicado: (2023)

Comparison of Adopted and Nonadopted Individuals Reveals Gene–Environment Interplay for Education in the UK Biobank
por: Cheesman, Rosa, et al.
Publicado: (2020)

Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease
por: Luczkowiak, Joanna, et al.
Publicado: (2018)

Convalescence via critical care collaboration
por: Shute, C, et al.
Publicado: (2014)

Pan-European Data Harmonization for Biobanks in ADOPT BBMRI-ERIC
por: Mate, Sebastian, et al.
Publicado: (2019)

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021)

Prevention of Wastage in Convalescent Depots
por: Brown, C. G.
Publicado: (1918)

REINFORCEMENT OF CONVALESCENT ANTIPOLIOMYELITIC SERUM IN THE MONKEY
por: Rhoads, C. P.
Publicado: (1931)

Ropner Convalescent Home, Stockton-On-Tees
por: Hillyer, C. M.
Publicado: (1898)

CHALLENGES IN THE PRODUCTION OF COVID-19 CONVALESCENT PLASMA – ANALYSIS OF DONOR RECRUITMENT
por: Sekiya, E.J., et al.
Publicado: (2020)

Use of convalescent plasma therapy in eight individuals with mild COVID-19
por: Ji, F., et al.
Publicado: (2020)

Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions
por: Mahapatra, S., et al.
Publicado: (2021)

Use of convalescent plasma therapy in SARS patients in Hong Kong
por: Cheng, Y., et al.
Publicado: (2004)

Childhood febrile illness and the risk of myopia in UK Biobank participants
por: Guggenheim, J A, et al.
Publicado: (2016)

Biobanking—Budgets and the Role of Pathology Biobanks in Precision Medicine
por: Andry, Chris, et al.
Publicado: (2017)

Convalescents
Publicado: (1907)

Convalescence
Publicado: (1875)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)
por: Saifuddin, S. R., et al.
Publicado: (2017)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: De Santis, Gil C., et al.
Publicado: (2022)

IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
por: Marsal, S, et al.
Publicado: (2010)

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
por: Rnjak, D., et al.
Publicado: (2021)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

Coagulation profile of human COVID-19 convalescent plasma
por: Klompas, Allan M., et al.
Publicado: (2022)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

SURVIVAL OF THE VIRUS OF POLIOMYELITIS IN THE ORAL AND NASAL SECRETION OF CONVALESCENTS
por: Kramer, S. D., et al.
Publicado: (1936)

Cannot write session to /tmp/vufind_sessions/sess_kcghpriq9lu7j7kiqc3islghh9